168759-60-2

Basic information

• Product Name: 7-bromo-4H-chromen-4-one
• Synonyms: 7-bromo-4H-chromen-4-one;4H-1-Benzopyran-4-one, 7-broMo-;7-Bromochromone
• CAS NO: 168759-60-2
• Molecular Formula: C₉H₅BrO₂
• Molecular Weight: 225.0388
• Mol File: 168759-60-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 154-159°C
• Boiling Point: 306.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.688±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 7-bromo-4H-chromen-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromo-4H-chromen-4-one(168759-60-2)
• EPA Substance Registry System: 7-bromo-4H-chromen-4-one(168759-60-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 168759-60-2(Hazardous Substances Data)

Usage

General Description

7-Bromo-4H-chromen-4-one, also known as 7-Bromo-4-coumarin, is a chemical compound with the molecular formula C9H5BrO2. It belongs to the chromen-4-one class of compounds and contains a bromine atom. 7-Bromo-4H-chromen-4-one is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active compounds. It is also known for its potential pharmacological activities, including anti-inflammatory, antimicrobial, and anticancer properties. 7-Bromo-4H-chromen-4-one has attracted significant attention from researchers due to its structural diversity and biological activities, making it a valuable target for drug discovery and development.

Upstream product

• 1016736-70-1 3-(3-bromophenoxy)propanenitrile 
• 591-20-8 3-Bromophenol 
• 18386-03-3 3-(3-bromophenoxy)propionic acid 
• 30186-18-6 4'-bromo-2'-hydroxyacetophenone 
• 288067-35-6 4-bromo-2-hydroxy-benzonitrile 

Downstream Products

• 18442-22-3 7-Bromo-2,3-dihydro-4H-chromen-4-one 
• 1260485-26-4 (E)-7-styrylchromone 
• 1180671-97-9 7-bromo-3-amino-chroman-4-one hydrochloride 
• 1180671-95-7 (E,Z)-7-bromochroman-4-one O-tosyl oxime 
• 1287312-22-4 7-(2-phenylethynyl)-4H-chromen-4-one 

Relevant articles and documents

Iron-Catalyzed Regioselective Decarboxylative Alkylation of Coumarins and Chromones with Alkyl Diacyl Peroxides

A facile iron-catalyzed decarboxylative radical coupling of alkyl diacyl peroxides with coumarins or chromones has been developed, affording a highly efficient approach to synthesize a variety of α-alkylated coumarins and β-alkylated chromones. The reaction proceeded smoothly without adding any ligand or additive and provided the corresponding products containing a wide scope of functional groups in moderate to excellent yields. This protocol was highlighted by its high regioselectivity, readily available starting materials, and operational simplicity.

Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants

The discovery of potent and pan-genotypic HCV NS5A inhibitors faces many challenges including the significant diversity among genotypes, substantial potency shift conferred on some key resistance-associated variants, inconsistent SARs between different genotypes and mutants, and the lacking of models of inhibitor/protein complexes for rational inhibitor design. As part of ongoing efforts on HCV NS5A inhibition at Merck, we now describe the discovery of a novel series of chromane containing NS5A inhibitors. SAR studies around the "Z" group of the tetracyclic indole scaffold explored fused bicyclic rings as alternates to the phenyl group of elbasvir (1, MK-8742) and identified novel chromane and 2,3-dihydrobenzofuran derivatives as "Z" group replacements offered good potency across all genotypes. This effort, incorporating the C-1 fluoro substitution at the tetracyclic indole core, led to the discovery of a new series of NS5A inhibitors, such as compounds 14 and 25-28, with significantly improved potency against resistance-associated variants, such as GT2b, GT1a Y93H, and GT1a L31V. Compound 14 also showed reasonable PK exposures in preclinical species (rat and dog).

ANTIVIRAL COMPOUNDS

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.